Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 3
1993 7
1994 4
1995 6
1996 2
1997 7
1998 5
1999 14
2000 12
2001 28
2002 9
2003 31
2004 24
2005 32
2006 60
2007 62
2008 70
2009 69
2010 100
2011 106
2012 121
2013 137
2014 125
2015 146
2016 173
2017 135
2018 165
2019 160
2020 41
Text availability
Article attribute
Article type
Publication date

Search Results

1,641 results
Results by year
Filters applied: . Clear all
Page 1
[Gene signatures for breast cancer, clinical utility and therapeutic applications].
Vargas-Aguilar VM, Arroyo-Alvarez K. Vargas-Aguilar VM, et al. Rev Med Inst Mex Seguro Soc. 2018 Mar-Apr;56(2):180-185. Rev Med Inst Mex Seguro Soc. 2018. PMID: 29906029 Review. Spanish.
Gene signatures quantify hormone receptors and proliferation genes, combining multivariate prediction models. Hormone-negative tumors have greater proliferation and the prognostic value is limited. ...Subsequent tests (Prosigna, EndoPredict, Breast Cancer Ind
Gene signatures quantify hormone receptors and proliferation genes, combining multivariate prediction models. Hormone-negative tumors
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Lehmann BD, et al. PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016. PLoS One. 2016. PMID: 27310713 Free PMC article.
Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling. ...Using five publicly available, neoadjuvant chemotherapy breast cancer gene
Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by …
Molecular mechanisms of breast cancer metastasis by gene expression profile analysis.
Zheng T, Wang A, Hu D, Wang Y. Zheng T, et al. Mol Med Rep. 2017 Oct;16(4):4671-4677. doi: 10.3892/mmr.2017.7157. Epub 2017 Aug 3. Mol Med Rep. 2017. PMID: 28791367 Free PMC article.
Expression profile microarray data GSE8977, which contained 22 stroma samples (15 were from normal breast and 7 were from invasive ductal carcinoma tumor samples), were obtained from the Gene Expression Omnibus database. ...Several genes crucial in the
Expression profile microarray data GSE8977, which contained 22 stroma samples (15 were from normal breast and 7 were from inva
Clinical utility of gene-expression signatures in early stage breast cancer.
Kwa M, Makris A, Esteva FJ. Kwa M, et al. Nat Rev Clin Oncol. 2017 Oct;14(10):595-610. doi: 10.1038/nrclinonc.2017.74. Epub 2017 May 31. Nat Rev Clin Oncol. 2017. PMID: 28561071 Review.
Assessments of standard clinical and pathological features have traditionally been used to determine the use of adjuvant systemic therapy in patients with early stage breast cancer; however, the ability to identify those who will benefit from adjuvant chem
Assessments of standard clinical and pathological features have traditionally been used to determine the use of adjuvant systemic therapy
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Risi E, Grilli A, Migliaccio I, Biagioni C, McCartney A, Guarducci C, Bonechi M, Benelli M, Vitale S, Biganzoli L, Bicciato S, Di Leo A, Malorni L. Risi E, et al. Breast Cancer Res Treat. 2018 Jul;170(2):329-341. doi: 10.1007/s10549-018-4766-2. Epub 2018 Mar 22. Breast Cancer Res Treat. 2018. PMID: 29564743
We performed a retrospective analysis exploring RBsig, a gene signature of RB loss, as a potential predictive marker of response to neoadjuvant chemotherapy in ER+/HER2+ breast cancer patients. METHODS: We selected clinical trials of neoadjuvant …
We performed a retrospective analysis exploring RBsig, a gene signature of RB loss, as a potential predictive marker of response
Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
Kwon MJ. Kwon MJ. Arch Pharm Res. 2019 Nov;42(11):947-961. doi: 10.1007/s12272-019-01189-y. Epub 2019 Nov 9. Arch Pharm Res. 2019. PMID: 31707598 Review.
Several multigene assays have been developed to predict the risk of distant recurrence and response to adjuvant therapy in early breast cancer. ...In this review, I summarize current multigene assays for breast cancer and discuss recent p …
Several multigene assays have been developed to predict the risk of distant recurrence and response to adjuvant therapy in ear …
PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM, Naoi Y, Shimazu K, Kagara N, Shimoda M, Tanei T, Miyake T, Kim SJ, Noguchi S. Ohara AM, et al. Breast Cancer Res Treat. 2019 Feb;173(3):533-543. doi: 10.1007/s10549-018-5020-7. Epub 2018 Oct 25. Breast Cancer Res Treat. 2019. PMID: 30361874
PURPOSE: There is an urgent need for the development of a predictor of response to chemotherapy for ER-positive breast cancer which is less chemosensitive than for ER-negative breast cancer in order to avoid unnecessary chemotherapy
PURPOSE: There is an urgent need for the development of a predictor of response to chemotherapy for ER-positive breast
Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling.
Goto-Yamaguchi L, Yamamoto-Ibusuki M, Yamamoto Y, Fujiki Y, Tomiguchi M, Sueta A, Takeshita T, Iwase H. Goto-Yamaguchi L, et al. Breast Cancer Res Treat. 2018 Nov;172(2):353-362. doi: 10.1007/s10549-018-4933-5. Epub 2018 Aug 27. Breast Cancer Res Treat. 2018. PMID: 30151737
PURPOSE: Neoadjuvant endocrine therapy (NAET) for estrogen receptor-positive primary breast cancer causes adequate tumor shrinkage, and is expected to be helpful for breast-conserving surgery, but the adaptation criteria, especially in regard to treatm …
PURPOSE: Neoadjuvant endocrine therapy (NAET) for estrogen receptor-positive primary breast cancer causes adequate tumo …
Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F, Zhao Y, Wei L, Li S, Liu J. Li F, et al. Cancer Biol Ther. 2018 Aug 3;19(8):695-705. doi: 10.1080/15384047.2018.1450116. Epub 2018 May 8. Cancer Biol Ther. 2018. PMID: 29621426 Free PMC article.
METHOD: We use needle biopsy breast cancer tissues prior to neoadjuvant chemotherapy(NCT) staining for CD33, Foxp3 and IDO by immunohistochemistry to evaluate whether they were correlated with subsequent treatment responses in breast cancer
METHOD: We use needle biopsy breast cancer tissues prior to neoadjuvant chemotherapy(NCT) staining for CD33, Foxp3 and …
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Gao Q, López-Knowles E, Cheang MCU, Morden J, Ribas R, Sidhu K, Evans D, Martins V, Dodson A, Skene A, Holcombe C, Mallon E, Evans A, Bliss JM, Robertson J, Smith I, Martin LA, Dowsett M; POETIC Trial Management Group and Trialists. Gao Q, et al. Breast Cancer Res. 2019 Dec 31;22(1):2. doi: 10.1186/s13058-019-1223-z. Breast Cancer Res. 2019. PMID: 31892336 Free PMC article. Clinical Trial.
BACKGROUND: Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy on gene expression and identify …
BACKGROUND: Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. …
1,641 results
Jump to page
Feedback